Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: A meta-analysis

Digestive Diseases and Sciences

Volumn 57, Issue 9, 2012, Pages 2304-2309

  Liang, Meilan ^a   Xu, Xinyu ^a   Gong, Yaoyao ^a   Tang, Yurong ^a   Lin, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Genetic polymorphisms; Inflammatory bowel diseases; Meta analysis; NF B1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B1; UNCLASSIFIED DRUG;

ARTICLE; CROHN DISEASE; DNA POLYMORPHISM; ENTERITIS; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; NF-KAPPA B; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RISK FACTORS;

EID: 84866427922     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2164-x     Document Type: Article

References (31)

1. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology. 2003;124:524-536.
2. De Vry CG, Prasad S, Komuves L, et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut. 2007;56:524-533. (Pubitemid 46580509)
3. Takedatsu H, Taylor KD, Mei L, et al. Linkage of Crohn's disease-related serological phenotypes: NF-κB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. Gut. 2009;58:60-67.
4. Le Beau MM, Ito C, Cogswell P, Espinosa R 3rd, Fernald AA, Baldwin AS Jr. Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NF-κB2) and the I kappa B/MAD-3 (NF-κBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively. Genomics. 1992;14:529-531.
5. Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene. 1993;8:191-193. (Pubitemid 23047246)
6. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 2004;382:393-409. (Pubitemid 39243905)
7. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NF-κB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35-45. (Pubitemid 38072133)
8. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NF-κB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet. 2005;32:401-405. (Pubitemid 41735580)
9. Oliver J, Gómez-García M, Paco L, et al. A functional polymorphism of the NF-κB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis. 2005;11:576-579. (Pubitemid 40826345)
10. Mirza MM, Fisher SA, Onnie C, et al. No association of the NF-κB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut. 2005;54:1205-1206. (Pubitemid 41025924)
11. Glas J, Török HP, Tonenchi L, et al. Role of the NF-κB1-94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis. 2006;12:606-611. (Pubitemid 43977742)
12. Latiano A, Palmieri O, Valvano MR, et al. Evaluating the role of the genetic variations of PTPN22, NF-κB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2007;13:1212-1219. (Pubitemid 47603099)
13. Szamosi T, Lakatos PL, Hungarian IBD Study Group, et al. The 3′UTR NF-κBIA variant is associated with extensive colitis in Hungarian IBD patients. Dig Dis Sci. 2009;54:351-359.
14. Lei Y, Deng C-S. Association of NF-κB1 -94ins/delATTG promoter polymorphism with ulcerative colitis in Chinese Han population of Hubei Province. World Chin J Digestol. 2009;17:2212-2216.
15. Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease. World J Gastroenterol. 2011;17:197-206.
16. Zou YF, Wang F, Feng XL, et al. Association of NF-κB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens. 2011;77:9-17.
17. Zou YF, Yuan FL, Feng XL, et al. Association between NF-κB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest. 2011;29:78-85.
18. Andersen V, Christensen J, Ostergaard M et al. Association of the nuclear receptors PXR, LXR and PPARγ with ulcerative colitis in the Danish population: a case-control study. Inflamm Bowel Dis. 2009;15:S29.
19. Borm ME, He J, Kelsall B, Peña AS, Strober W, Bouma G. A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models. Gastroenterology. 2005;128:74-85. (Pubitemid 40039960)
20. Farmer MA, Sundberg JP, Bristol IJ, et al. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci USA. 2001;98:13820-13825. (Pubitemid 33115982)
21. Chang M, Lee AJ, Fitzpatrick L, Zhang M, Sun SC. NF-kappaB1 p105 regulates T cell homeostasis and prevents chronic inflammation. J Immunol. 2009;182:3131-3138.
22. Tomczak MF, Erdman SE, Poutahidis T, et al. NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. J Immunol. 2003;171:1484-1492. (Pubitemid 36900083)
23. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet. 1999;64:808-816. (Pubitemid 30460424)
24. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA. 1998;95:7502-7507. (Pubitemid 28293282)
25. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008;263:591-596. (Pubitemid 351678589)
26. Ishikawa H, Claudio E, Dambach D, Raventós-Suárez C, Ryan C, Bravo R. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-κB1) but expressing p50. J Exp Med. 1998;187:985-996. (Pubitemid 28176399)
27. Erdman S, Fox JG, Dangler CA, Feldman D, Horwitz BH. Typhlocolitis in NF-kappa B-deficient mice. J Immunol. 2001;166:1443-1447.
28. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson PF. Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappaB p50. Mol Cell Biol. 1998;18:5678-5689. (Pubitemid 28450519)
29. Visekruna A, Joeris T, Seidel D, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest. 2006;116:3195-3203. (Pubitemid 44878633)
30. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol. 2004;135:64-73. (Pubitemid 38067929)
31. Tomczak MF, Erdman SE, Davidson A, et al. Inhibition of Helicobacter hepaticus-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. J Immunol. 2006;177:7332-7339. (Pubitemid 44715103)